Close Menu

NEW YORK (GenomeWeb) – Illumina said at the close of the market on Tuesday that sales of its HiSeq X Ten and NextSeq 500 instruments helped drive record revenues of $512.4 million in the fourth quarter of 2014.

During a conference call discussing the company's 2014 fourth quarter and full-year results, CEO Jay Flatley provided an update of the company's sequencing and array businesses, discussed a future liquid biopsy oncology product, and gave an update on its noninvasive prenatal testing business and progress with the US Food and Drug Administration on developing a cleared NIPT.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.